Management of hepatitis B patients with antiviral resistance

Antiviral Therapy

Volumn 9, Issue 6, 2004, Pages 1013-1026

  Fung, Scott K ^a   Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; CIRCULAR DNA; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; INTERFERON; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA PRECURSOR; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BIOCHEMICAL BREAKTHROUGH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DETERIORATION; DISEASE EXACERBATION; DRUG CHOICE; DRUG EFFICACY; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER DYSFUNCTION; LIVER HISTOLOGY; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN MOTIF; RECURRENT INFECTION; REVERSE TRANSCRIPTION; RISK FACTOR; SALVAGE THERAPY; SEROCONVERSION; VIROLOGIC BREAKTHROUGH INFECTION; VIRUS INFECTION; VIRUS REPLICATION; YMDD MOTIF;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; RISK FACTORS;

EID: 11144270970     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S & Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119:172-180.
2. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Wu PC, Dent JC, Edmundson S, Condreay LD & Chien RN; on behalf of the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
3. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, Ng KY, Nicholls GJ, Dent JC & Leung NW. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. Journal of Gastroenterology & Hepatology 2004; 19:1276-1282.
4. Qi X, Snow A, Thibault V, Zhu Y, Curtis M, Hadziyannis SJ, Brosgart CL, Currie G, Arterburn S, Gibbs CS, Miller MD & Xiong S. Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy (abstract). Journal of Hepatology 2004; 40:A57.
5. Peters M, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df D, Sullivan M, Kleber K, Ebrahimi R, Xiong S & Brosgart CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91-101.
6. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve JP, Lama N, James C, Wulfsohn MS, Namini H, Westland C, Xiong S, Choy GS, Van Doren S, Fry J & Brosgart CL; Behalf of the Adefovir Dipovoxil Study 435 International Investigators Group. Adefovir dipivoxil therapy for lamivudine-resistam: hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38:1419-1427.
7. Marcellin P, Chang TT, Lim SG, Tong M, Sievert W, Schiffman M, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J & Brosgart CL; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e-antigen-positive chronic hepatitis B. New England Journal of Medicine 2003; 348:808-816.
8. Locarnini S. Molecular virology of hepatitis B virus. Seminars in Liver Disease 2004; 24:3-10.
9. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC & McDade H. Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences, USA 1996; 93:4398-4402.
10. Zeuzem S, de Man RA, Honkoop P, Roth WK, Schalm SW & Schmidt JM. Dynamics of hepatitis B virus infection in vivo. Journal of Hepatology 1997; 27:431-436.
11. Roberts JD, Bebenek K & Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988; 242:1171-1173.
12. Summers J & Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29:403-415.
13. Fourel I, Cullen TM, Saputelli J, Aldrich CF, Schaffer P, Averett DR, Pugh J & Mason WS. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. Journal of Virology 1994; 68:8321-8330.
14. Poch O, Sauvaget I, Delarue M & Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO Journal 2004; 8:3867-3874.
15. Najera I, Holguin A, Quinones-Mateu ME, Munoz-Fernandez MA, Najera R, Lopez-Galindez C & Domingo E. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. Journal of Virology 1995; 69:23-31.
16. Kobayashi S, Ide T & Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. Journal of Hepatology 2001; 34:584-586.
17. Stuyver L, Locarnini S, Lok A, Richman DD, Carman WF, Dienstag JL & Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751-757.
18. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C & Christopherson C. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases 1995; 171:1411-1419.
19. Gao HQ, Boyer P, Sarafianos S, Arnold E & Hughes S. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. Journal of Molecular Biology 2000; 300:403-418.
20. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N & Condreay LD. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:1670-1677.
21. Hadziyannis S, Papatheodoridis GV, Dimou E, Laras A & Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847-851.
22. Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. Journal of Hepatology 2003; 39:5124-5132.
23. Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K & Kumada H. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and retakeover by wild type after cessation of therapy. Hepatology 1998; 27:1711-1716.
24. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yohida H, Carrilho FJ & Omata M. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transciptase inhibitors. Journal of Clinical Investigation 1999; 103:1635-1640.
25. Fu L & Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochemical Pharmacology 1998; 55:1567-1572.
26. Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K & Sablon E. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. Journal of Clinical Microbiology 2002; 40:3729-3734.
27. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T & Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. Journal of Medical Virology 1999; 59:270-276.
28. Bock C, Tillmann H, Torresi J, Klempnauer J, Locarnini S, Manns M & Trautwein C. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264-273.
29. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. Journal of Clinical Virology 2002; 25:97-106.
30. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini S, Fyfe J, Sozzi T & Jackson DC. Vaccine-induced anti-HBs escape mutants of hepatitis B virus arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293:305-313.
31. Gish R, Leung N, Wang C, Corey L, Sacks L, Fried M, Wright T, Huy T, Chan F, Rousseau F, Mommeja-Marin H, Snow A, Anderson J, Rigney A & Mondou E. Antiviral activity, safety and incidence of resistance in chronically infected hepatitis B (CHB) patients given once daily emtricitabine for 2 years. Hepatology 2003; 38:A372.
32. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann W & Han S. Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B (abstract). Hepatology 2003; 38:A219.
33. Zoulim F, Pichoud C, Wang Z, Aguesse-Germonb S & Trepo C. Hepatitis B virus genome variability during famciclovir therapy. Hepatology 1997; 26:A1200.
34. Tillmann H, Trautwein C, Bock C, Glowenka M, Kruger M, Boker K, Jackel E, Pichlmayr R, Condreay L, Bruns I, Deslaurias M, Gauthier J & Manns M. Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation. Hepatology 1997; 26:A1202.
35. Westland CE, Yang H, Delaney WE, Gibbs CS, Miller MD, Wulfsohn M, Fry J, Brosgart C, Xiong S & 437 and 438 Study Teams. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38:96-103.
36. Xiong S, Yang H, Westland CE, Delaney WE, Colledge D, Bartholomeusz A, Thibault V, Benhamou Y, Angus P, Wulfsohn M, Gibbs CS, Fry J, Brosgart C & Locarnini S. Resistance surveillance of HBeAg- chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV). Journal of Hepatology 2003; 38:182.
37. Bartholomeusz A, Tehan BG & Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antiviral Therapy 2004; 9:149-160.
38. Angus P, Vaughan R, Xiong S, Yang H, Delaney WE, Gibbs CS, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A & Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297.
39. Yang H, Qi X, Das K, Arnold E, Westland CE, Delaney WE. Brosgart CL, Gibbs CS, Miller MD & Xiong S. In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation rtN236T in the HBV polymerase. Journal of Hepatology 2004; 40:A383.
40. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson F, Thomas N & Dehertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123:1831-1838.
41. Barbara G, Zechini F, Pellicelli A, Francavilla R, Scotto G, Bacca D, Bruno M, Babudieri S, Annese M, Matarazzo F, Di Stefano G & Barbarini G; Lamivudine Italian Study Group Investigators. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. Journal of Hepatology 2001; 35:406.
42. Sanantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Guastadisegni A, Facciorusso D, Gravinese E, Andriulli A & Pastore G. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. Journal of Hepatology 2002; 36:799.
43. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J & Gray DF. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46:562-568.
44. Sung JJY, Lai JY, Zeuzem S, Chow WC, Heathcote E, Perrillo R, Brosgart C, Woessner M, Scott SA & Campbell FM. A randomised double-blind phase 11 study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B: week 52 analysis (abstract). Journal of Hepatology 2003; 38:25A.
45. Lok A & McMahon B. Chronic hepatitis B. Hepatology 2001; 34:1225-1241.
46. Lok ASF & McMahon B. AASLD Practice Guidelines: chronic hepatitis B. Hepatology 2004.
47. Papatheodoridis G, Dimou E, Laras A, Papadimitropoulos V & Hadziyannis S. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 32:219-226.
48. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M & Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. New England Journal of Medicine 1999; 341:1256-1263.
49. Lai CL, Chien RN, Leung N, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent IC, Barber J, Stephenspn SL & Gray DF. A one-year trial or lamivudine for chronic hepatitis B. New England Journal of Medicine 1998; 339:61-68.
50. Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM & Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clinical Infectious Diseases 2003; 37:113-128.
51. Pas SD, de Man RA, Fries E, van Nunen AB, Osterhaus AD & Niesters HGM. The dynamics of mutations in the polymerase gene of hepatitis B virus during and after lamivudine therapy. Journal of Clinical Virology 2002; 25:63-71.
52. Hussain M, Chu CJ, Sablon E & Lok ASF. Rapid and sensitive assays for the determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. Journal of Clinical Microbiology 2003; 41:3699-3705.
53. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-572.
54. Dienstag J, Goldin R, Heathcote EJ, Hann H, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105-117.
55. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff E, Dienstag J, Heathcote EJ, Little NR, Griffiths DA, Gardner SD & Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722.
56. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP & Boker KHW. Lamivudine and low dose hepatitis B immune globulin as prophylaxis of hepatitis B reinfection after liver transplantation: possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. Journal of Hepatology 2001; 34:895-902.
57. Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, Shaw J, Burroughs N, Rand D, Cane P, Martin B, Buchan S, Boxall E, Barmat S, Gutekunst K, McMaster P & Elias E. High pretreatment serum hepatitis B virus titer predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. Journal of Hepatology 1999; 30:715-721.
58. Thibault V, Aubron-Olivier C, Agut H & Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16:131-133.
59. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS & Richman DD. Antiretroviral drug-resistance among patients recently infected with HIV. New England Journal of Medicine 2002; 347:385-394.
60. Yerly S, Kaiser L, Race E, Bru JP, Clavel F & Perrin L. Transmission of antiretroviral drug-resistant HIV-1 variants. Lancet 1999; 354:729-733.
61. Lai CL, Dienstag J, Schiff E, Leung N, Atkins M, Hunt C, Brown N, Woessner M, Boehme R & Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clinical Infectious Diseases 2003; 36:687-696.
62. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trepo C & Zoulim F. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32:1078-1088.
63. Zhou T, Saputelli J, Aldrich CF, Deslauriers M, Condreay L & Mason WS. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrobial Agents & Chemotherapy 1999; 43:1947-1954.
64. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H & Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34:785-791.
65. Mutimer D, Pillay D, Cook P, Ratcliffe D, O'Donnell K, Dowling D, Shaw J, Elias E & Cane PA. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. Journal of Infectious Diseases 2000; 181:713-716.
66. Locarnini S. Antiviral-resistant hepatitis B: current state of knowledge. AASLD Hepatitis Single Topic Conference: New Directions in the Treatment of Hepatitis B. 12-13 March 2004, Chicago, Ill., USA.
67. Lok ASF & McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39:857-861.
68. Lok A, Heathcote J & Hoofnagle J. Management of hepatitis B 2000, summary of a workshop. Gastroenterology 2001; 120:1828-1853.
69. NIH. Guidelines for the use of antiretroviral therapy in HIV-infected adults and adolescents. NIH website 2004.
70. Chien RN, Liaw YF, Atkins M & Asian Hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30:770-774.
71. Lai CL, Lin HJ, Lau JN, Lok AS, Wu PC, Chung HT, Wong LK, Leung MP & Yeung CY. Effect of recombinant alpha 2 Interferon with or without prednisone in Chinese HBsAg carrier children. Quarterly Journal of Medicine 1991; 78:155-163.
72. Lok AS, Lai CL, Wu PC & Leung EK. Long term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2:298-302.
73. Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, Ma OC, Lauder IJ, Ng CP & Chung HT. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102:2091-2097.
74. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M & Gardner SD. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36:186-194.
75. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA & Chodakewitz JA. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection-and prior anti-retroviral therapy. New England Journal of Medicine 1997; 337:734-739.
76. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA & Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less. New England Journal of Medicine 1997; 337:725-733.
77. Liaw YF, Chien RN & Yeh CT. No benefit to continue lamivudine after the emergence of YMDD mutations. Antiviral Therapy 2004; 9:145-148.
78. Gish R, Chang T, Hadziyannis S, Cianciara J, Rizzetto M, Schiff E, Pastore G, Jackson R, Thiry A & Hindes R. Lamivudine-refractory hepatitis B patients can be safely switched directly to entecavir 1 mg daily therapy (abstract). Journal of Hepatology 2004; 40:A428.
79. Kuo A, Dienstag J & Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clinical Gastroenterology & Hepatology 2004; 2:266-272.
80. Schiff E, Chang T. Gish R, Hadziyannis S, Cianciara J, Rizzetto M, Pastore G, Cross A & Hindes R. Entecavir 1.0 mg is consistently superior to lamivudine at 48 weeks across multiple baseline HBV disease characteristics in lamivudine-refractory patients. Journal of Hepatology 2004; 40:A442.
81. van Bommel F, Wunsche T, Schnurmann D, Bergk A, Wiedenmann B, Hopf U & Berg T. A comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus (HBV) infection. Hepatology 2003; 38:A246.
82. Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S & Colonno RJ. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrobial Agents & Chemotherapy 2002; 46:2525-2532.